232 related articles for article (PubMed ID: 29905398)
41. Rasburicase: future directions in tumor lysis management.
Hochberg J; Cairo MS
Expert Opin Biol Ther; 2008 Oct; 8(10):1595-604. PubMed ID: 18774926
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
[TBL] [Abstract][Full Text] [Related]
43. Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
Shin HY; Kang HJ; Park ES; Choi HS; Ahn HS; Kim SY; Chung NG; Kim HK; Kim SY; Kook H; Hwang TJ; Lee KC; Lee SM; Lee KS; Yoo KH; Koo HH; Lee MJ; Seo JJ; Moon HN; Ghim T; Lyu CJ; Lee WS; Choi YM
Pediatr Blood Cancer; 2006 Apr; 46(4):439-45. PubMed ID: 16123985
[TBL] [Abstract][Full Text] [Related]
44. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
[TBL] [Abstract][Full Text] [Related]
45. Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
Agrawal AK; Feusner JH
Br J Haematol; 2011 Apr; 153(2):275-7. PubMed ID: 21255003
[No Abstract] [Full Text] [Related]
46. Rasburicase in the prevention and treatment of tumour lysis syndrome.
Mayne N; Keady S; Thacker M
Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
[TBL] [Abstract][Full Text] [Related]
47. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
Eaddy M; Seal B; Tangirala M; Davies EH; O'Day K
Am J Health Syst Pharm; 2010 Dec; 67(24):2110-4. PubMed ID: 21116002
[TBL] [Abstract][Full Text] [Related]
48. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
[TBL] [Abstract][Full Text] [Related]
49. Clarifying the role of rasburicase in tumor lysis syndrome.
Sood AR; Burry LD; Cheng DK
Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.
Trifilio SM; Pi J; Zook J; Golf M; Coyle K; Greenberg D; Newman D; Koslosky M; Mehta J
Bone Marrow Transplant; 2011 Jun; 46(6):800-5. PubMed ID: 20818444
[TBL] [Abstract][Full Text] [Related]
51. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Oldfield V; Perry CM
Drugs; 2006; 66(4):529-45. PubMed ID: 16597166
[TBL] [Abstract][Full Text] [Related]
52. Fixed-Dose Recombinant Urate Oxidase in the Treatment of Paediatric Tumour Lysis Syndrome: A Regional Cancer Centre Experience.
L A; Reddy JM; Chebbi PG; Kumar N; Ar AK; M P; B S AK
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3897-3901. PubMed ID: 34967569
[TBL] [Abstract][Full Text] [Related]
53. [Rasburicase therapy may cause hydrogen peroxide shock].
Góth L
Orv Hetil; 2008 Aug; 149(34):1587-90. PubMed ID: 18708312
[TBL] [Abstract][Full Text] [Related]
54. Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
Hooman N; Otukesh H
Iran J Kidney Dis; 2011 Mar; 5(2):130-2. PubMed ID: 21368393
[TBL] [Abstract][Full Text] [Related]
55. Rasburicase for the treatment and prevention of hyperuricemia.
Yim BT; Sims-McCallum RP; Chong PH
Ann Pharmacother; 2003; 37(7-8):1047-54. PubMed ID: 12841818
[TBL] [Abstract][Full Text] [Related]
56. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
[TBL] [Abstract][Full Text] [Related]
57. SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Bertrand Y; Mechinaud F; Brethon B; Mialou V; Auvrignon A; Nelken B; Notz-Carrère A; Plantaz D; Patte C; Urbieta M; Baruchel A; Leverger G;
J Pediatr Hematol Oncol; 2008 Apr; 30(4):267-71. PubMed ID: 18391694
[TBL] [Abstract][Full Text] [Related]
58. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
Eaddy M; Seal B; Tangirala K; Davies EH; O'Day K
Appl Health Econ Health Policy; 2012 Nov; 10(6):431-40. PubMed ID: 23013428
[TBL] [Abstract][Full Text] [Related]
59. Rasburicase versus intravenous allopurinol for non-malignancy-associated acute hyperuricemia in paediatric cardiology patients.
Moss JD; Wu M; Axelrod DM; Kwiatkowski DM
Cardiol Young; 2019 Sep; 29(9):1160-1164. PubMed ID: 31451121
[TBL] [Abstract][Full Text] [Related]
60. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy.
Hutcherson DA; Gammon DC; Bhatt MS; Faneuf M
Pharmacotherapy; 2006 Feb; 26(2):242-7. PubMed ID: 16466328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]